Urogen has been Granted Orphan Drug Designation from the US FDA for its Innovative Treatment of UTUC

Urogen Pharma, a clinical stage specialty pharmaceutical company focused on treatment of urological diseases, announced today that MitoGel, a sustained release formulation of Mitomcin C, has been granted orphan-drug designation by the U.S Food and Drug Administration (“FDA”) for the … Continue reading

Posted in News | Comments Off on Urogen has been Granted Orphan Drug Designation from the US FDA for its Innovative Treatment of UTUC

UroGen is recruiting clinical centers for the OLYMPUS trial for UTUC patients

UroGen Pharma is planning to start the OLYMPUS trial during 2016 and is looking for centers in US and Europe. The study will evaluate  the feasibility, safety, durability and ablative effect of MMC Mixed With TCGel in patients with Upper Tract Urothelial … Continue reading

Posted in News | Leave a comment

UroGen presented its Interstitial Cystitis safety and feasibility pilot study results during ICS 2014, Brazil

Dr Koby Stav from the Neurourology Division, Department of Urology, Assaf Harofeh Medical Center, presented the results of the study named “Safety and feasibility of intravesical instillation of botulinum toxin A in a novel hydrogel-based slow release delivery system in PBS/IC … Continue reading

Posted in News | Leave a comment